MaxHealth Medicine Group
Established in 2009, the MaxHealth Medical Group works with world-class manufacturers of pharmaceutical products and medical technologies to open up the Chinese market to them. MaxHealth has an interest in medical technologies that can transform existing treatment processes and bring about significant benefits to patient and physicians. The company partners with innovative companies to commercialise medical technologies for the Chinese market through investments, joint ventures and technology licensing.
1 past transactions
Zilico
Corporate Round in 2018
Zilico Limited is a medical diagnostics company focused on developing innovative devices for cancer detection, particularly cervical cancer. Founded in 2006 and based in Manchester, United Kingdom, with an additional office in Sheffield, Zilico utilizes electrical impedance spectroscopy technology to enhance diagnostic accuracy and provide real-time results. Its primary product, ZedScan, is designed to assess cervical epithelial tissue objectively during colposcopy, thereby reducing the subjectivity associated with traditional diagnostic methods. The company is advancing its offerings with two applications aimed at improving referral and screening processes for neoplastic conditions. By enhancing the ability to detect cervical intraepithelial neoplasia, Zilico aims to support healthcare professionals in delivering better diagnostic accuracy and optimizing cancer screening programs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.